This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.
Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.
Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.
Key clinical takeaways:
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0
Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/ntrk-connect/
X: https://x.com/PresOnc_Connect
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.
This podcast is developed by cor2ed.com
Published March 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Testing to treatment of BRAF-mutant metastatic NSCLC In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of...
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase...
Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are...